Tag: disease modifying therapies
MSIF puts a spotlight on the ethical use of off-label disease modifying therapies for MS
New publication from MSIF on ethical use of off-label DMTs receives global endorsement
How different disease modifying therapies can delay progression
A new study examined different disease modifying therapies and their ability to slow the onset of secondary progressive MS.
Study suggests improvement in MS employment outcomes
New research, involving 874 people who had used disease-modifying therapies during the previous 5 years, has shown a link between more effective disease-modifying therapies and an increased level of employment, work attendance and productivity at work.